Silo PharmaSILO
SILO
About: SILO Pharma Inc is a developmental stage biopharmaceutical company developing novel therapeutics that address underserved conditions including stress-induced psychiatric disorders, chronic pain conditions, and central nervous system (CNS) diseases. It focuses on developing traditional therapies and psychedelic treatments in novel formulations and drug delivery systems. The company's primary program, SPC-15, is an intranasal treatment targeting PTSD and stress-induced anxiety disorders.
Employees: 3
0
Funds holding %
of 7,312 funds
–
Analysts bullish %
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
76% more capital invested
Capital invested by funds: $162K [Q4 2024] → $285K (+$123K) [Q1 2025]
1.45% more ownership
Funds ownership: 4.1% [Q4 2024] → 5.55% (+1.45%) [Q1 2025]
13% less funds holding
Funds holding: 15 [Q4 2024] → 13 (-2) [Q1 2025]
33% less first-time investments, than exits
New positions opened: 4 | Existing positions closed: 6
33% less repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 3
Research analyst outlook
We haven’t received any recent analyst ratings for SILO.
Financial journalist opinion
Based on 3 articles about SILO published over the past 30 days
Neutral
GlobeNewsWire
4 days ago
Silo Pharma Advances PTSD Drug SPC-15 Toward Planned 2025 IND Submission with Pre-Clinical Study Data Expected in Q3 2025
Planned submission of IND application in 2025; Phase 1 clinical trial to follow if IND application approved
Neutral
GlobeNewsWire
2 weeks ago
Silo Pharma Enters into Letter of Intent to Form Joint Venture with Hoth Therapeutics to Develop Obesity Treatment Targeting $16 Billion Global Market
Technology Co-Developed by the U.S. Department of Veterans Affairs and Emory University NEW YORK, June 25, 2025 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“Silo” or the “Company”), a developmental stage biopharmaceutical company focused on novel therapeutics and drug delivery systems, today announced that it has entered into a non-binding letter of intent to form a strategic 50:50 joint venture with Hoth Therapeutics, Inc. (Nasdaq: HOTH) to develop and commercialize a potential treatment for obesity and metabolic disease based on technology Hoth has exclusively licensed from the U.S. Department of Veterans Affairs (VA) that was co-developed by the VA and Emory University. The novel therapeutic platform centers on glial cell line-derived neurotrophic factor (GDNF), a VA-invented biologic with demonstrated anti-obesity effects and metabolic regulation in preclinical models.
Neutral
PRNewsWire
2 weeks ago
Hoth Therapeutics (HOTH) and Silo Pharma (NASDAQ: SILO) today announced the formation of a 50/50 joint venture to develop a first-in-class GDNF-based therapy licensed from the U.S. Department of Veterans Affairs. The therapy targets obesity and fatty liver disease.
*Hoth Therapeutics and Silo Pharma Launch Joint Venture to Commercialize VA-Invented Obesity Drug Targeting $100B+ Global Market Exclusive License from U.S. Department of Veterans Affairs to Advance GDNF-Based Therapy for Obesity and Fatty Liver Disease NEW YORK , June 25, 2025 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH) and Silo Pharma, Inc. (NASDAQ: SILO) today announced the formation of a strategic joint venture to develop and commercialize a first-in-class treatment for obesity and metabolic disease based on technology exclusively licensed from the U.S. Department of Veterans Affairs (VA). The novel therapeutic platform centers on Glial Cell Line-Derived Neurotrophic Factor (GDNF), a VA-invented biologic with demonstrated anti-obesity effects and metabolic regulation in preclinical models.
Neutral
GlobeNewsWire
1 month ago
Silo Pharma Secures Biomarker Patent for Novel PTSD Therapeutic SPC-15 as Clinical Trial Nears
SARASOTA, FL, June 11, 2025 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“Silo” or the “Company”), a developmental stage biopharmaceutical company focused on novel therapeutics and drug delivery systems, today announced that the U.S. Patent and Trademark Office (USPTO) had issued a Notice of Allowance for U.S. Patent Application No. 17/954,858 (titled “Biomarkers for Efficacy of Prophylactic Treatments Against Stress-Induced Affective Disorders”) that Silo licenses from Columbia University.
Neutral
GlobeNewsWire
1 month ago
Silo Pharma Board of Directors Approves Purchase of Bitcoin as Treasury Reserve Asset
Strategic decision positions Company to diversify treasury holdings with a long-term digital store of value Strategic decision positions Company to diversify treasury holdings with a long-term digital store of value
Neutral
GlobeNewsWire
1 month ago
Silo Pharma Partners with Resyca for IND-Supporting Intranasal Drug-Device Study of PTSD Drug SPC-15
Study is expected to deliver final device data and documentation needed for planned FDA IND submission Study is expected to deliver final device data and documentation needed for planned FDA IND submission
Neutral
GlobeNewsWire
1 month ago
Silo Pharma Announces Closing of $2 Million Public Offering
SARASOTA, FL, May 16, 2025 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“Silo” or the “Company”), a developmental stage biopharmaceutical company focused on novel therapeutics and drug delivery systems, closed on the previously announced public offering of 3,333,338 shares of common stock (or pre-funded warrants in lieu thereof), together with series A-1 warrants (“Series A-1 Warrants”) to purchase up to 3,333,338 shares of common stock and series A-2 warrants (“Series A-2 Warrants”) to purchase up to 3,333,338 shares of common stock at a combined public offering price of $0.60 per share (or pre-funded warrant in lieu thereof) and associated Series A-1 Warrant and Series A-2 Warrant. The Series A-1 Warrants have an exercise price of $0.60 per share, are exercisable upon issuance and expire five years thereafter. The Series A-2 Warrants have an exercise price of $0.60 per share, are exercisable upon issuance and expire eighteen months thereafter.
Neutral
GlobeNewsWire
1 month ago
Silo Pharma Announces Pricing of $2 Million Public Offering
SARASOTA, FL, May 15, 2025 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“Silo” or the “Company”), a developmental stage biopharmaceutical company focused on novel therapeutics and drug delivery systems, today announced the pricing of a public offering of 3,333,338 shares of common stock (or pre-funded warrants in lieu thereof), together with series A-1 warrants (“Series A-1 Warrants”) to purchase up to 3,333,338 shares of common stock and series A-2 warrants (“Series A-2 Warrants”) to purchase up to 3,333,338 shares of common stock at a combined public offering price of $0.60 per share (or pre-funded warrant in lieu thereof) and associated Series A-1 Warrant and Series A-2 Warrant. The Series A-1 Warrants will have an exercise price of $0.60 per share, are exercisable upon issuance and will expire five years thereafter. The Series A-2 Warrants will have an exercise price of $0.60 per share, are exercisable upon issuance and will expire eighteen months thereafter. The closing of the offering is expected to occur on or about May 16, 2025, subject to the satisfaction of customary closing conditions.
Neutral
GlobeNewsWire
1 month ago
Silo Pharma Selects Veloxity Labs for Bioanalytical IND-Enabling Study for our Novel Intranasal PTSD Therapy, SPC-15
SARASOTA, FL, May 14, 2025 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“Silo” or the “Company”), a developmental stage biopharmaceutical company focused on novel therapeutics and drug delivery systems, today announced that it has engaged Veloxity Labs, LLC for bioanalysis supporting the ongoing investigational new drug (IND)-enabling GLP (Good Laboratory Practice)-compliant toxicology and toxicokinetics study of its lead asset, SPC-15, an intranasal prophylactic treatment for post-traumatic stress disorder (PTSD). “We look forward to working with Veloxity Labs for GLP sample analysis in our current safety study of SPC-15,” said Eric Weisblum, CEO of Silo.
Neutral
GlobeNewsWire
1 month ago
Silo Pharma Advances PTSD Drug SPC-15 Toward First-in-Human Trial with Key Safety Study Initiated at Frontage Laboratories
Clear Regulatory Path to Clinical Trials for Intranasal PTSD Therapy Targeting Multi-Billion-Dollar Market Clear Regulatory Path to Clinical Trials for Intranasal PTSD Therapy Targeting Multi-Billion-Dollar Market
Charts implemented using Lightweight Charts™